story of the week
Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib vs Dupilumab in Patients With Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Dermatitis
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis
Dermatitis 2023 Dec 18;[EPub Ahead of Print], JI Silverberg, M de Bruin-Weller, BM Calimlim, X Hu, SA Ofori, AM Platt, HD Teixeira, K Eyerich, JP ThyssenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.